WEKO3
アイテム
{"_buckets": {"deposit": "1f54b6fc-fbb2-45fa-a10f-04b21acaab60"}, "_deposit": {"created_by": 2, "id": "855", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "855"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00000855", "sets": ["108"]}, "author_link": ["4040", "4048", "4038", "4045", "4041", "4049", "4047", "4035", "4046", "4050", "4044", "4039", "4037", "4043", "4036", "4042"], "item_3_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "7", "bibliographicPageStart": "1", "bibliographicVolumeNumber": "64", "bibliographic_titles": [{"bibliographic_title": "Acta medica Nagasakiensia"}]}]}, "item_3_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Aim: This study compared the efficacy and safety of Bmab+oral 5-Fluorourasil (Bmab+o-5-FU) including Bmab+Capecitabine (Cape) with that of intensive chemotherapy including L-OHP or CPT-11 for patients with metastatic colorectal cancer (mCRC).\nMethods: Between January 2006 and February 2017, 40 elderly (?70 years) chemotherapy-naive patients with mCRC (male/female=22/18; median age, 76.0 years) were retrospectively reviewed. The treatment regimens were Bmab+o-5-FU (n=19)and intensive regimens (n=21). Intensive regimens comprised 17 L-OHP and 4 CPT-11 doublet chemotherapies.\nResults: The median progression-free survival (PFS) with Bmab+o-5-FU and intensive regimens was 281 and 215 days, respectively. The median survival time with Bmab+o-5-FU and intensive regimens was 961 and 1,002 days, respectively. No significant differences were observed in the overall survival or PFS between Bmab+o-5-FU and the other regimens. The disease control rate was 94.7% with Bmab+o-5-FU and 81.0% with intensive regimens. The rate of grade ?3 hematologicaladverse events was 5.3% for Bmab+o-5-FU and 15.8% for intensive regimens.\nConclusions: With its similar survival benefit to intensive regimens, high disease control rate and good feasibility, Bmab+o-5-FU seems a fine treatment choice for elderly mCRC patients.", "subitem_description_type": "Abstract"}]}, "item_3_description_64": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Acta medica Nagasakiensia, 64(1), pp.1-7; 2020", "subitem_description_type": "Other"}]}, "item_3_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagasaki University School of Medicine"}]}, "item_3_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00508430", "subitem_source_identifier_type": "NCID"}]}, "item_3_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00016055", "subitem_source_identifier_type": "ISSN"}]}, "item_3_text_62": {"attribute_name": "sortkey", "attribute_value_mlt": [{"subitem_text_value": "01"}]}, "item_3_text_63": {"attribute_name": "出版者別言語", "attribute_value_mlt": [{"subitem_text_value": "長崎大学医学部"}]}, "item_3_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kobayashi, Kazuma"}], "nameIdentifiers": [{"nameIdentifier": "4035", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tetsuo, Hanako"}], "nameIdentifiers": [{"nameIdentifier": "4036", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamaguchi, Shun"}], "nameIdentifiers": [{"nameIdentifier": "4037", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Shinichiro"}], "nameIdentifiers": [{"nameIdentifier": "4038", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Torashima, Yasuhiro"}], "nameIdentifiers": [{"nameIdentifier": "4039", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Inoue, Yusuke"}], "nameIdentifiers": [{"nameIdentifier": "4040", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okada, Satomi"}], "nameIdentifiers": [{"nameIdentifier": "4041", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Enjoji, Takahiro"}], "nameIdentifiers": [{"nameIdentifier": "4042", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuba, Sayaka"}], "nameIdentifiers": [{"nameIdentifier": "4043", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kosaka, Taiichiro"}], "nameIdentifiers": [{"nameIdentifier": "4044", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Adachi, Tomohiko"}], "nameIdentifiers": [{"nameIdentifier": "4045", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hidaka, Masaaki"}], "nameIdentifiers": [{"nameIdentifier": "4046", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamanouchi, Kosho"}], "nameIdentifiers": [{"nameIdentifier": "4047", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kanetaka, Kengo"}], "nameIdentifiers": [{"nameIdentifier": "4048", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takatsuki, Mitsuhisa"}], "nameIdentifiers": [{"nameIdentifier": "4049", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Eguchi, Susumu"}], "nameIdentifiers": [{"nameIdentifier": "4050", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-18"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ActMed64_1.pdf", "filesize": [{"value": "830.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 830100.0, "url": {"label": "ActMed64_1.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/855/files/ActMed64_1.pdf"}, "version_id": "24c84fd1-013f-47f0-bc91-557d1e7d20f4"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "elderly patient", "subitem_subject_scheme": "Other"}, {"subitem_subject": "colorectal cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "bevacizumab", "subitem_subject_scheme": "Other"}, {"subitem_subject": "o-5-FU", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Bevacizumab +oral 5-fluorourasil versus intensive chemotherapy for the treatment of elderly patients with metastatic colorectal cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Bevacizumab +oral 5-fluorourasil versus intensive chemotherapy for the treatment of elderly patients with metastatic colorectal cancer"}]}, "item_type_id": "3", "owner": "2", "path": ["108"], "permalink_uri": "http://hdl.handle.net/10069/40041", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-06-17"}, "publish_date": "2020-06-17", "publish_status": "0", "recid": "855", "relation": {}, "relation_version_is_last": true, "title": ["Bevacizumab +oral 5-fluorourasil versus intensive chemotherapy for the treatment of elderly patients with metastatic colorectal cancer"], "weko_shared_id": 2}
Bevacizumab +oral 5-fluorourasil versus intensive chemotherapy for the treatment of elderly patients with metastatic colorectal cancer
http://hdl.handle.net/10069/40041
http://hdl.handle.net/10069/40041ebb6ce74-f2b1-4485-bfea-5f24f1c83760
名前 / ファイル | ライセンス | アクション |
---|---|---|
ActMed64_1.pdf (830.1 kB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-06-17 | |||||
タイトル | ||||||
タイトル | Bevacizumab +oral 5-fluorourasil versus intensive chemotherapy for the treatment of elderly patients with metastatic colorectal cancer | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | elderly patient | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | colorectal cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | bevacizumab | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | o-5-FU | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
著者 |
Kobayashi, Kazuma
× Kobayashi, Kazuma× Tetsuo, Hanako× Yamaguchi, Shun× Ito, Shinichiro× Torashima, Yasuhiro× Inoue, Yusuke× Okada, Satomi× Enjoji, Takahiro× Kuba, Sayaka× Kosaka, Taiichiro× Adachi, Tomohiko× Hidaka, Masaaki× Yamanouchi, Kosho× Kanetaka, Kengo× Takatsuki, Mitsuhisa× Eguchi, Susumu |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Aim: This study compared the efficacy and safety of Bmab+oral 5-Fluorourasil (Bmab+o-5-FU) including Bmab+Capecitabine (Cape) with that of intensive chemotherapy including L-OHP or CPT-11 for patients with metastatic colorectal cancer (mCRC). Methods: Between January 2006 and February 2017, 40 elderly (?70 years) chemotherapy-naive patients with mCRC (male/female=22/18; median age, 76.0 years) were retrospectively reviewed. The treatment regimens were Bmab+o-5-FU (n=19)and intensive regimens (n=21). Intensive regimens comprised 17 L-OHP and 4 CPT-11 doublet chemotherapies. Results: The median progression-free survival (PFS) with Bmab+o-5-FU and intensive regimens was 281 and 215 days, respectively. The median survival time with Bmab+o-5-FU and intensive regimens was 961 and 1,002 days, respectively. No significant differences were observed in the overall survival or PFS between Bmab+o-5-FU and the other regimens. The disease control rate was 94.7% with Bmab+o-5-FU and 81.0% with intensive regimens. The rate of grade ?3 hematologicaladverse events was 5.3% for Bmab+o-5-FU and 15.8% for intensive regimens. Conclusions: With its similar survival benefit to intensive regimens, high disease control rate and good feasibility, Bmab+o-5-FU seems a fine treatment choice for elderly mCRC patients. |
|||||
書誌情報 |
Acta medica Nagasakiensia 巻 64, 号 1, p. 1-7, 発行日 2020-06 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00016055 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00508430 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
出版者 | ||||||
出版者 | Nagasaki University School of Medicine | |||||
出版者別言語 | ||||||
長崎大学医学部 | ||||||
sortkey | ||||||
01 | ||||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Acta medica Nagasakiensia, 64(1), pp.1-7; 2020 |